Long non-coding RNA KRT8P41/miR-193a-3p/FUBP1 axis modulates the proliferation and invasion of chordoma cells

Wen, Hua; Fu, Yang; Zhu, Yapeng; Tao, Siyue; Shang, Xifu; Li, Zhongqi; You, Tao; Zhang, Wenzhi

doi:10.1016/j.jbo.2021.100392

Cited by 5 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two studies were multicenter, which includes different populations, increasing the strength of the study ( 21 , 34 ). With regard to study design, 5 studies were prospective (7.3%) ( 26 , 35 – 38 ) and 63 studies were retrospective (92.7%) ( 21 – 25 , 27 – 34 , 39 – 87 ).…”

Section: Resultsmentioning

confidence: 99%

Prognostic molecular biomarkers in chordomas: A systematic review and identification of clinically usable biomarker panels

Rubino

Alvarez‐Breckenridge²,

Akdemir³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Introduction and objectiveDespite the improvements in management and treatment of chordomas over time, the risk of disease recurrence remains high. Consequently, there is a push to develop effective systemic therapeutics for newly diagnosed and recurrent disease. In order to tailor treatment for individual chordoma patients and develop effective surveillance strategies, suitable clinical biomarkers need to be identified. The objective of this study was to systematically review all prognostic biomarkers for chordomas reported to date in order to classify them according to localization, study design and statistical analysis.MethodsUsing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we systematically reviewed published studies reporting biomarkers that correlated with clinical outcomes. We included time-to-event studies that evaluated biomarkers in skull base or spine chordomas. To be included in our review, the study must have analyzed the outcomes with univariate and/or multivariate methods (log-rank test or a Cox-regression model).ResultsWe included 68 studies, of which only 5 were prospective studies. Overall, 103 biomarkers were analyzed in 3183 patients. According to FDA classification, 85 were molecular biomarkers (82.5%) mainly located in nucleus and cytoplasm (48% and 27%, respectively). Thirty-four studies analyzed biomarkers with Cox-regression model. Within these studies, 32 biomarkers (31%) and 22 biomarkers (21%) were independent prognostic factors for PFS and OS, respectively.ConclusionOur analysis identified a list of 13 biomarkers correlating with tumor control rates and survival. The future point will be gathering all these results to guide the clinical validation for a chordoma biomarker panel. Our identified biomarkers have strengths and weaknesses according to FDA’s guidelines, some are affordable, have a low-invasive collection method and can be easily measured in any health care setting (RDW and D-dimer), but others molecular biomarkers need specialized assay techniques (microRNAs, PD-1 pathway markers, CDKs and somatic chromosome deletions were more chordoma-specific). A focused list of biomarkers that correlate with local recurrence, metastatic spread and survival might be a cornerstone to determine the need of adjuvant therapies.

show abstract

Section: Resultsmentioning

confidence: 99%

Prognostic molecular biomarkers in chordomas: A systematic review and identification of clinically usable biomarker panels

Rubino

Alvarez‐Breckenridge²,

Akdemir³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…For example, LOC554202 may play an anti-tumor role in chordoma via suppressing proliferation and invasion of chordoma cells [12] . LncRNA KRT8P41 acted as a tumor promoter via accelerating chordoma cell proliferation and invasion [13] . In addition, the former report indicated that lncRNA X-inactive specific transcript (XIST) was upregulated in chordoma, which might promote the development of chordoma [14] .…”

Section: Introductionmentioning

confidence: 99%

XIST sponges miR-320d to promote chordoma progression by regulating ARF6

Wang

Tang

Guo

2022

Journal of Bone Oncology

View full text Add to dashboard Cite

Dysregulation of noncoding RNA in chordoma; implications in identifying potential targets for novel therapeutic approaches

Ghosh,

Ghosh

2024

Mol Biol Rep

View full text Add to dashboard Cite

Long non-coding RNA KRT8P41/miR-193a-3p/FUBP1 axis modulates the proliferation and invasion of chordoma cells

Abstract: Highlights lncRNA KRT8P41 potentially serves as an oncogenic lncRNA in chordoma. miR-193a binds to lncRNA KRT8P41 and FUBP1 3′UTR. LncRNA KRT8P41/miR-193a axis modulates chordoma cell aggressiveness through FUBP1.

Cited by 5 publications

References 33 publications

Prognostic molecular biomarkers in chordomas: A systematic review and identification of clinically usable biomarker panels

Prognostic molecular biomarkers in chordomas: A systematic review and identification of clinically usable biomarker panels

XIST sponges miR-320d to promote chordoma progression by regulating ARF6

Dysregulation of noncoding RNA in chordoma; implications in identifying potential targets for novel therapeutic approaches

Contact Info

Product

Resources

About